Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00397488 · OUTCOME

Overall Objective Response

Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium · Source last updated 2016-01-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
2 years

What was measured

Response rate as measured by RECIST criteria. The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). In general, the patient's best response assignment will depend on the achievement of both measurement and confirmation criteria

Groups in this outcome

Sunitinib

Sunitinib in patients with metastatic urothelial carcinoma.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Sunitinib71

Reported measurements

Partial Response (PR)
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Sunitinib3Not reportedNot reportedNot reportedNot reported
Stable Disease (SD)
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Sunitinib29Not reportedNot reportedNot reportedNot reported
Progression of Disease (POD)
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Sunitinib39Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        3
    title
    Partial Response (PR)
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        29
    title
    Stable Disease (SD)
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        39
    title
    Progression of Disease (POD)
denoms
  1. counts
    1. group Id
      OG000
      value
      71
    units
    Participants
description
Response rate as measured by RECIST criteria. The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). In general, the patient's best response assignment will depend on the achievement of both measurement and confirmation criteria
groups
  1. description
    Sunitinib in patients with metastatic urothelial carcinoma.
    id
    OG000
    title
    Sunitinib
param Type
NUMBER
reporting Status
POSTED
time Frame
2 years
title
Overall Objective Response
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice